Recombinant IFITM1 Monoclonal Antibody (AN300169P)
-
-
-
- +1
For research use only.
| Verified Samples |
Verified Samples in WB: K562 in IHC: Human breast cancer in IF: K562, A431 |
| Dilution | WB: 1:1000；IHC-P: 1:200-1:2000；ICC/IF: 1:200-1:500；FC: 1:200-1:500；IP: 1:20-1:50 |
| Isotype | IgG |
| Host | Rabbit |
| Reactivity | Human |
| Applications | WB, IHC-P, ICC/IF, FC, IP |
| Clonality | Recombinant;Monoclonal |
| Immunogen | A synthetic peptide corresponding to the center region of the Human IFITM1 |
| Abbre | IFITM1 |
| Synonyms | LEU, IFI, IFITM, IFITM1, CD225, DSPA2a, IFI17, LEU13, 9-27, Leu-13, 45562 |
| Swissprot | |
| Calculated MW | 14 kDa |
| Observed MW |
14 kDa
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Concentration | 1 mg/mL |
| Buffer | 0.2 μm filtered solution in PBS |
| Purification Method | Protein A |
| Research Areas | Immunology, Signal Transduction, Stem Cells, Cancer |
| Clone | A1283 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronavirus (SARS-CoV), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration. |
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.sample_type}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
No files available. Please enter the correct identification code in the search area to query the relevant documents.
| Title | Status | Valid until | Action | |
|---|---|---|---|---|
| {{v.文件名}} | {{v.status_str}} | {{v.timestamp_str}} | Download | / |
*Note：Please download the relevant files within the validity period. After expiration, file preview and download will not be available on the page.
Videos
Resources
Contact with Us
Houston, Texas, 77079, USA
